O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer

David M O’malley ,Michelle Wilson,Vít Drochýtek,Stephanie Hume,Linda Van Le,Gabriel Lindahl,Robert T Morris ,Toon Van Gorp,Sandra Goble,Keiichi Fujiwara,Bradley Monk,Ramez N Eskander ,Andrea Jewell,Athina Christopoulou,Dearbhaile Catherine Collins ,Fuat Demirkıran ,Myong Cheol Lim,Paul Bessette,John P Diaz ,Rebecca Kristeleit

doi:10.1136/ijgc-2022-igcs.28

O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer

David M O’malley , Michelle Wilson + Show 18 more

Open Access

https://doi.org/10.1136/ijgc-2022-igcs.28

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Dec 1, 2022
Citations: 2

#Maintenance Treatment In Patients #First-line Maintenance Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesIn ATHENA-MONO (NCT03522246), progression-free survival (PFS) improved with first-line rucaparib maintenance treatment vs placebo in patients with advanced ovarian cancer (OC), regardless of molecular characteristics (median PFS: 20.2 vs 9.2...

Full Text